All In Biotech

Drug Trial Radar · NCT01616927

Study of Lanreotide to Treat Polycystic Kidney Disease

The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD

Last checked: Nov 20, 2026Latest source record: May 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 2012

Primary completion

Aug 2017

Study completion Dec 2017

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Leiden University Medical Center; Erasmus Medical Center; Radboud University Medical Center
First posted
Jun 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys, in most patients leading to end stage renal disease. It is the most common hereditary renal disease with a prevalence of approximately 1 in 1,000 persons. The majority of patients also have progressive cyst formation in the liver, leading to pain, gastrointestinal discomfort and sometimes the need for liver transplantation. At present there is no proven therapeutic intervention to slow the rate of disease progression in human ADPKD. The development of renoprotective treatments that are well tolerated, is therefore of major importance. In this respect, somatostatin analogues are promising for especially polycystic liver disease, but also for the renal phenotype. However, the studies that have been performed thus far with these agents, were underpowered and of too short duration to reach a definitive conclusion on the potential reno- and hepatoprotective efficacy of somatostatin analogues. Therefore, the present study is designed as a randomised clinical trial with sufficient duration of follow-up to investigate whether the somatostatin analogue Lanreotide slows progression of polycystic kidney and liver disease in ADPKD-patients. To this end, 300 ADPKD patients, aged 18-60years, with an eGFR 30-60 ml/min/1.73 m2) will be randomized 1:1 to standard care or monthly subcutaneous lanreotide injections on top off standard care. These 300 subjects will go through 15 study visits in 3 years and 1 follow up visit. During these visits, questionnaires will be filled in, physical examinations will be performed, blood will be drawn and urine collected. After study completion, rate of renal function decline in lanreotide treated subjects will be compared to that of subject who received standard care.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

  • LanreotideDrug

    Lanreotide will be administered once every 4 weeks as a subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in renal functionTime frame: serial eGFR measurements from month 3 until end of treatment visit (month 30)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Groningen

    Groningen, Netherlands

  • Leiden University Medical Center

    Leiden, Netherlands

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • Erasmus Medisch Centrum

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.